Alimera Sciences Inc - Aset Bersih saben Siji Saham ALIM

Alimera Sciences (ALIM) is implementing ESG standards in production and optimizing packaging while scaling sales of retinal drugs under the umbrella of a new holding company. This chart of book value per share demonstrates a fundamental trend, where 0.74 serves as the final level mark. Alimera Sciences is developing a unique long-term drug delivery method that replaces frequent injections with a single procedure lasting several years.

The growth of the current BVPS value reflects the capitalization of the exclusivity of the drug Iluvien and the high margins of the Alimera Sciences (ALIM) business. This indicator is calculated as the ratio of equity minus preferred shares to the total number of shares outstanding, determining the intrinsic value of an investor's stake and the price floor of the asset in a fundamental valuation of the company.